Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin

Gregory M. Brown a,*, Ramanujam Karthikeyan b, Seithikurippu R. Pandi-Perumal c, Daniel P. Cardinali d

a Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, ON M5T 1R8, Canada
b Independent Researcher, Naraynapuram, Madurai, TN, India
c Somnogen Canada Inc, Toronto, ON, Canada
d Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina

ARTICLE INFO

Keywords:
Autism Spectrum Disorder
COVID-19
SARS-CoV-2
Melatonin

ABSTRACT

Patients with Autism Spectrum Disorder (ASD) may be particularly prone to develop COVID-19. An unusual extended course of COVID-19 disease illness has been reported in one ASD patient and a group of patients have COVID-19 disease in a neurodevelopmental facility. It has been widely reported that many of those with ASD have substantial sleep disorders with low levels of melatonin and various genetic alterations related to melatonin production have been found. Several lines of evidence point to a substantial role of melatonin in the body’s innate defense system including acting as a scavenger, an antioxidant and modulating the immune system. We therefore hypothesize that melatonin deficiency may predispose those ASD patients who have low melatonin output to COVID-19 disease. Potential implications for treatment are discussed.

Autism Spectrum Disorder (ASD)

The prevalence of Autism Spectrum Disorder (ASD) has been reported as 1 in 132 [1]. It is a devastating illness, first appearing in childhood, with symptoms that include difficulties with social communication and social interaction, often with cognitive deficits and unusual behavior that includes restricted, repetitive activities and interests [2]. Sleep patterns are often disrupted which can lead to major difficulties for families and caregivers as the patients waking during sleep inevitably wakes those caregivers. The severity of sleep problems parallels that of other symptoms and may aggravate those symptoms [3].

COVID-19 disease and ASD

COVID-19 disease is a multiorgan disease due to SARS-CoV-2 viral infection, that become pandemic in early 2020 [4]. It has been hypothesized that those with ASD may be predisposed to COVID-19 disease because of modifications at the immune and genetic levels [5,6]. Recently, a case series of 16 ASD patients admitted to a neurodevelopmental unit with COVID-19 like symptoms was reported [7]. Eleven of these patients were shown to have COVID-19 disease by reverse transcriptase polymerase chain reaction (RT-PCR) or by serology at follow-up, of these patients only one required oxygen therapy. A recent case report describes a nine-year-old Italian child in a nursing home with exceptionally high viral load and an extended duration of viral shedding Grossi and Teruzzi, [8]. Initial symptoms of cough and nasal discharge disappeared within two days and no clinical signs of lung involvement could be detected. However, quantitative RT-PCR indicated an extremely high viral load. A gradually decreasing load was seen over the following twelve weeks until negative tests were found, but only after 82 days. ASD patients with COVID-19 disease may be a major problem to the health care system; those who are severely intellectually disabled may be unable to communicate symptoms effectively thus monitoring, prevention and testing are doubly important [9].

Melatonin and ASD

A potentially significant factor in ASD is the finding of low urinary levels of the melatonin metabolite 6-sulphatoxymelatonin (aMT6s). In 23 ASD patients aged 4–10 years overall nocturnal aMT6s levels were reduced [10] together with increased N3 sleep, decreased N2 sleep and

* Corresponding author.
E-mail address: gregm.brown@utoronto.ca (G.M. Brown).

https://doi.org/10.1016/j.mehy.2021.110544
Received 22 December 2020; Accepted 14 February 2021
Available online 18 February 2021
0306-9877/© 2021 Published by Elsevier Ltd.
increased daytime sleepiness [10]. In another study 43 patients with ASD showed lower urinary aMT6s levels (8.26 µg per 24 h vs 18.00 µg per 24 h) both during nighttime and daytime in comparison to 26 controls matched for age, sex and pubertal status [11]. In that study the amount of aMT6s decrease correlated with the severity of illness. Most ASD studies looking for melatonin excretion, except for one [12] reported decreased melatonin output. Another controlled study of 77 children with ASD and 84 controls aged 2.5 to 15.5 years reported that those with ASD had lower nighttime aMT6s than the controls with no difference in the daytime levels [13]. aMT6s levels in the ASD group were associated with sleep disturbance but not with ASD severity. In a study of 83 children with ASD aged 5 to 10, it was reported that aMT6s levels were increased in families with higher income but decreased with increased neurological problems [14]. Manuani and coworkers examined the relationship between the pineal gland volume (PGV) estimated by MRI and early morning melatonin levels in 215 participants, 78 with ASD, 90 unaffected relatives and 47 controls. Although both melatonin and PGV were lower in patients than controls, the melatonin deficit appeared to be more related to group than to PCV. The authors stated that the findings support a deficit in the melatonin synthetic pathway as a possible main cause [15].

**Melatonin synthesis in ASD**

Genetic variation in synthesis of melatonin has been reported in ASD. In a unique subgroup of ASD children selected for having sleep onset delay, higher frequencies were reported of variants that decrease acetylserotonin O-methyltransferase (ASMT, the enzyme that determines the quantity of melatonin synthesized), as well as of those that decrease cytochrome P450 1A2 (CYP1A2, the enzyme that metabolizes melatonin) [16]. Two different polymorphisms in the promoter have been reported for ASMT, moreover a splicing mutation was reported in two families [17–19] In 2065 children, ages 4–18, from the Simons Simplex Collection (SSC) no relationship was found between any gene variants and sleep problems [20]. The authors suggest that sleep problems may be related to translational or posttranslational effects of these genes or to additional ones modifying the sleep system.

**Melatonin and COVID-19**

Melatonin is a multipotential body substance: it is not just a pineal hormone but is synthesized widely in the body and acts as a potent antioxidant, scavenger, modulates the immune system and modulates macrophage function [21]. It is synthesized in cerebral mitochondria, where it can counteract overproduction of radical oxygen species at the site of their generation during electron transport [22]. In the immune system it suppresses innate immunity while facilitating antibody production. Melatonin suppresses NLRP3 inflammasomes, proinflammatory cytokine activation and facilitates switching of highly inflammatory M1 macrophages to anti-inflammatory M2 macrophages [23–25]. In numerous animal viral diseases it has been shown to greatly enhance survival. Moreover, in several instances of human sepsis adjunctive treatment with melatonin has improved patient outcome [26]. The structure and physico-chemical properties of melatonin have been examined using electronic structure methods and molecular-mechanics tools as a predictor of melatonin’s bioactivity against the coronavirus 2 proteins. Based on the docking scores obtained, the authors proposed that melatonin could be effective to defend against the viral load in vulnerable populations [27]. Recently it was reported in a case series that 36 to 72 mg of melatonin daily po is a helpful adjuvant in patients with severe pneumonic COVID-19 disease [28]. The analysis of 26,779 records of patients in a COVID-19 database revealed melatonin was associated with an improved outcome [29]. A prospective study of 791 intubated COVID-19 patients showed that melatonin was associated with survival [30]. In the first reported randomly controlled trial of melatonin in COVID-19 patients, 3 mg was administered three times daily to hospitalized patients (24 given melatonin vs 20 none), the melatonin treatment group had significantly less symptoms and were discharged earlier from hospital [31].
Treatment implications

Based on the hypothesis that low melatonin can be a reason for susceptibility to the SARS-CoV-2 virus we postulate that adequate melatonin levels will be preventative. It is known that there is genetic variation in the melatonin synthesis pathway in some ASD patients. In others the sleep irregularity that frequently is seen in ASD may result in a decrease in circulating melatonin because of waking during the night and exposure to light. Light and especially blue light will suppress melatonin production by the pineal gland, so it is important to regulate sleep to prevent this if it is possible [32]. Two treatments described recently can be of assistance [3]. A comprehensive program of sleep hygiene that improves sleep can be effective in reducing exposure to light at times that would impair melatonin secretion. Another possible treatment is the use of melatonin as a sleep aid [3].

Conclusion

We hypothesize that a low melatonin output, found in those with ASD due to either genetic variation in the synthetic enzyme pathway or to frequent nighttimes with exposure to light that suppresses melatonin synthesis by the pineal gland, may lead to susceptibility to COVID-19 disease. Further we propose that treatment with melatonin to correct nighttime waking and treatment with melatonin are both treatments that may prevent COVID-19 disease or reduce its severity in ASD patients.

Sources of funding

No funding is declared.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med 2015;45(3):601–13.
[2] Association AP. Diagnostic and statistical manual of mental disorders, 5th ed. Vol. 5. Arlington, VA: American Psychiatric Association; 2013.
[3] Kotharikeyan R, Cardinale DP, Shukunhala V, Spence DW, Brown GM, Pandi-Perumal SR. Understanding the role of sleep and its disturbances in autism spectrum disorder. Int J Neurosci. 2020:1–14. https://doi.org/10.1080/00207654.2019.1711377.
[4] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Research: Nature Reviews Microbiology; 2020.
[5] Steinman G. COVID-19 and autism. Med Hypotheses 2020;1:42.
[6] Lima ME de S, Barros LCM, Araújo GF. Could autism spectrum disorders be a risk factor for COVID-19? Medical Hypotheses. 2020 Nov 1:44.
[7] Nolace L, Craverco C, Abbos A, Mazda-Walter B, Bleibtreu A, Pereira N, et al. Autism and COVID-19: a case series in a neurodevelopmental unit. J Clin Med 2020;9(9):2037.
[8] Grossi E, Teruzzi V. Exceptionally high COVID-19 viral load and a very long duration of shedding in a young pauci-symptomatic child with autism resident in an Italian nursing home. J Infect. 2020:8(3), 2020.
[9] Baghdadi A, Picot MC, Miot S, Munir K. A call to action to implement effective COVID-19 prevention and screening of individuals with severe intellectual and developmental disabilities. J Autism Develop Disorders 2020.
[10] Leu RM, Beyderman L, Botzolakis EJ, Surydyka K, Wang L, Malow BA. Relation of melatonin to sleep architecture in children with autism. J Autism Dev Disorder 2011; 41(4):227–33.
[11] Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biological psychiatry. 2005;57(0006–3223):2:134–8.
[12] Ritvo ER, Ritvo R, Yawiler A, Brothers A, Freeman BJ, Plot S. Elevated daytime melatonin concentrations in autism: a pilot study. Eur Child Adolesc Psychiatry 1993:2.
[13] Babinka R, Silkenkova L, Stebelová K, Waczuilkova I, Celusakova H, Vidnovovcova M, et al. Urinary levels of 6-sulphatoxymelatonin and its metabolic products in children with autism spectrum disorder. Br J Nutr Med J 2019;120(11):849–55.
[14] Bridgenmoorn C, Cochran DM, Howe YJ, Pawlowski K, Zimmerman AW, Anderson GM, et al. Investigating potential biomarkers in autism spectrum disorder. Front Integr Neurosci 2019:2:13.
[15] Maruani A, Dumas G, Baggia A, Traut N, Peyre H, Cohen-Freuza A, et al. Morning plasma melatonin differences in autism: beyond the impact of pineal gland volume. Frontiers. Psychiatry. 2019:10(FEB).
[16] Veitch OJ, Pendergast JS, Allen MJ, Leu RM, Johnson CH, Elsea SH, et al. Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder andcorrelated sleep onset delay. J Autism Dev Disorder 2015;45(1):100–10.
[17] Melke J, Gouban Botros H, Chaste P, Betancur C, Nygren G, Ankanaa H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Molecular psychiatry. 2008;13(1359–4184; 1):90–8.
[18] Jonsson L, Anczkarsater H, Zettergren A, Westberg L, Walum H, Lundstroem S, et al. Association between ASMT and autistic-like traits in children from a Swedish nationwide cohort. Psychiatric Genetics 2014;24(1):21–7. Available from: http://journals.lww.com/00041444-201402000-00003.
[19] Jonsson L, Ljunggren E, Bremer A, Pedersen C, Landin M, Thureson K, et al. Mutation screening of melatonin-related genes in patients with autism spectrum disorders. BMC Med Genomics 2010.
[20] Johansson AEJ, Dorman JS, Chasens ER, Feeley CA, Devlin B. Variations in genes related to sleep patterns in children with autism spectrum disorder. Biol Res Nurs 2019:21(1):335–42.
[21] Cardinali DP, Brown GM, Pandi-Perumal SR. Can melatonin be a potential "silver bullet" in treating COVID-19 patients? Diseases. 2020;8:4(4).
[22] Hardeland R. Melatonin and the electron transport chain. Cell Mol Life Sci 2017;74 (21):3388–96.
[23] Xu X, Wang G, Ai I, Shi J, Zhang J, Chen YX. Melatonin suppresses TLR9-triggered proinflammatory cytokine production in macrophages by inhibiting ERK1/2 and AKT activation. Scientific Reports [Internet]. 2018;8(1):15579. Available from: https://doi.org/10.1038/s41598-018-34011-8.
[24] Xia Y, Chen S, Zeng S, Zhao Y, Zhu C, Deng B, et al. Melatonin in macrophage biology: current understanding and future perspectives. J Pineal Res 2019.
[25] Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int J Endocrinol 2017; 2017.
[26] Biancatelli RMLC, Berrill M, Mohammed YH, Marik PE. Melatonin for the biological psychiatry: current understanding and future perspectives. J Pineal Res 2019.
[27] Al-Zaqri N, Pooventhiran T, Alsalme A, Warad I, John AM, Thomas R. Structural manifestations and drug repurposing for COVID-19. PLoS Biol. 2020 Nov 6;18(11).
[28] Hardeland R. Melatonin and the electron transport chain. Cell Mol Life Sci 2017;74 (21):3388–96.
[29] Al-Zaqri N, Pooventhiran T, Alsalme A, Warad I, John AM, Thomas R. Structural manifestations and drug repurposing for COVID-19. PLoS Biol. 2020 Nov 6;18(11).
[30] Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv: the preprint server for health sciences [Internet]. 2020 Oct 18; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33083812.
[31] Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, et al. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int J Endocrinol 2019; 2019;
[32] Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellectual Disability Res: JIDR. 2010;54(6):547–55.